Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023…
News
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy…
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy…
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human…
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human…
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand…
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand…
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease;…
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease;…
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in…
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in…
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 15, 2023 (GLOBE…
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 15, 2023 (GLOBE…
Gritstone bio and Genevant Sciences Announce Option and License Agreement
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA…
Gritstone bio and Genevant Sciences Announce Option and License Agreement
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA…
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in…